These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

210 related articles for article (PubMed ID: 34485907)

  • 41. OLIG2 maintenance is not essential for diffuse intrinsic pontine glioma cell line growth but regulates tumor phenotypes.
    Liao Y; Luo Z; Deng Y; Zhang F; Rao R; Wang J; Xu L; Kumar SS; Sengupta S; DeWire-Schottmiller M; Berry K; Garrett M; Fouladi M; Drissi R; Lu QR
    Neuro Oncol; 2021 Jul; 23(7):1183-1196. PubMed ID: 33539525
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Pediatric Diffuse Midline Gliomas H3 K27M-Mutant and Non-Histone Mutant Midline High-Grade Gliomas in Neurofibromatosis Type 1 in Comparison With Non-Syndromic Children: A Single-Center Pilot Study.
    Garibotto F; Madia F; Milanaccio C; Verrico A; Piccardo A; Tortora D; Piatelli G; Diana MC; Capra V; Garrè ML; Rossi A; Morana G
    Front Oncol; 2020; 10():795. PubMed ID: 32582540
    [No Abstract]   [Full Text] [Related]  

  • 43. Targeting Mutant PPM1D Sensitizes Diffuse Intrinsic Pontine Glioma Cells to the PARP Inhibitor Olaparib.
    Wang Z; Xu C; Diplas BH; Moure CJ; Chen CJ; Chen LH; Du C; Zhu H; Greer PK; Zhang L; He Y; Waitkus MS; Yan H
    Mol Cancer Res; 2020 Jul; 18(7):968-980. PubMed ID: 32229503
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Dual HDAC and PI3K Inhibition Abrogates NFκB- and FOXM1-Mediated DNA Damage Response to Radiosensitize Pediatric High-Grade Gliomas.
    Pal S; Kozono D; Yang X; Fendler W; Fitts W; Ni J; Alberta JA; Zhao J; Liu KX; Bian J; Truffaux N; Weiss WA; Resnick AC; Bandopadhayay P; Ligon KL; DuBois SG; Mueller S; Chowdhury D; Haas-Kogan DA
    Cancer Res; 2018 Jul; 78(14):4007-4021. PubMed ID: 29760046
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Cutting Edge Therapeutic Insights Derived from Molecular Biology of Pediatric High-Grade Glioma and Diffuse Intrinsic Pontine Glioma (DIPG).
    Bailey CP; Figueroa M; Mohiuddin S; Zaky W; Chandra J
    Bioengineering (Basel); 2018 Oct; 5(4):. PubMed ID: 30340362
    [TBL] [Abstract][Full Text] [Related]  

  • 46. DNA Methylation Profiles Are Stable in H3 K27M-Mutant Diffuse Midline Glioma Neurosphere Cell Lines.
    Schniederjan MJ; Potnis C; Vasudevaraja V; Moser CD; Watson B; Snuderl M; MacDonald T; Rogers BB
    Children (Basel); 2024 Apr; 11(4):. PubMed ID: 38671709
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Epigenetic programming of pediatric high-grade glioma: Pushing beyond proof of concept to clinical benefit.
    Groves A; Cooney TM
    Front Cell Dev Biol; 2022; 10():1089898. PubMed ID: 36589742
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Anti-tumor efficacy of anti-GD2 CAR NK-92 cells in diffuse intrinsic pontine gliomas.
    Zuo P; Li Y; He C; Wang T; Zheng X; Liu H; Wu Z; Zhang J; Liao X; Zhang L
    Front Immunol; 2023; 14():1145706. PubMed ID: 37251413
    [TBL] [Abstract][Full Text] [Related]  

  • 49. DECIPHER pooled shRNA library screen identifies PP2A and FGFR signaling as potential therapeutic targets for diffuse intrinsic pontine gliomas.
    Schramm K; Iskar M; Statz B; Jäger N; Haag D; Słabicki M; Pfister SM; Zapatka M; Gronych J; Jones DTW; Lichter P
    Neuro Oncol; 2019 Jul; 21(7):867-877. PubMed ID: 30943283
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma.
    Lee CH; Yu JR; Granat J; Saldaña-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D
    Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Diffuse Intrinsic Pontine Glioma Cells Are Vulnerable to Mitotic Abnormalities Associated with BMI-1 Modulation.
    Senthil Kumar S; Sengupta S; Zhu X; Mishra DK; Phoenix T; Dyer L; Fuller C; Stevenson CB; DeWire M; Fouladi M; Drissi R
    Mol Cancer Res; 2020 Nov; 18(11):1711-1723. PubMed ID: 32801164
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Deceptive morphologic and epigenetic heterogeneity in diffuse intrinsic pontine glioma.
    Bugiani M; Veldhuijzen van Zanten SEM; Caretti V; Schellen P; Aronica E; Noske DP; Vandertop WP; Kaspers GJL; van Vuurden DG; Wesseling P; Hulleman E
    Oncotarget; 2017 Sep; 8(36):60447-60452. PubMed ID: 28947983
    [TBL] [Abstract][Full Text] [Related]  

  • 53. A tumor suppressor role for EZH2 in diffuse midline glioma pathogenesis.
    Dhar S; Gadd S; Patel P; Vaynshteyn J; Raju GP; Hashizume R; Brat DJ; Becher OJ
    Acta Neuropathol Commun; 2022 Apr; 10(1):47. PubMed ID: 35395831
    [TBL] [Abstract][Full Text] [Related]  

  • 54. EZH2i EPZ-6438 and HDACi vorinostat synergize with ONC201/TIC10 to activate integrated stress response, DR5, reduce H3K27 methylation, ClpX and promote apoptosis of multiple tumor types including DIPG.
    Zhang Y; Zhou L; Safran H; Borsuk R; Lulla R; Tapinos N; Seyhan AA; El-Deiry WS
    Neoplasia; 2021 Aug; 23(8):792-810. PubMed ID: 34246076
    [TBL] [Abstract][Full Text] [Related]  

  • 55. New
    Plessier A; Le Dret L; Varlet P; Beccaria K; Lacombe J; Mériaux S; Geffroy F; Fiette L; Flamant P; Chrétien F; Blauwblomme T; Puget S; Grill J; Debily MA; Castel D
    Oncotarget; 2017 Aug; 8(32):52543-52559. PubMed ID: 28881750
    [TBL] [Abstract][Full Text] [Related]  

  • 56. High frequency of H3 K27M mutations in adult midline gliomas.
    Ebrahimi A; Skardelly M; Schuhmann MU; Ebinger M; Reuss D; Neumann M; Tabatabai G; Kohlhof-Meinecke P; Schittenhelm J
    J Cancer Res Clin Oncol; 2019 Apr; 145(4):839-850. PubMed ID: 30610375
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas.
    Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S
    Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Re-programing Chromatin with a Bifunctional LSD1/HDAC Inhibitor Induces Therapeutic Differentiation in DIPG.
    Anastas JN; Zee BM; Kalin JH; Kim M; Guo R; Alexandrescu S; Blanco MA; Giera S; Gillespie SM; Das J; Wu M; Nocco S; Bonal DM; Nguyen QD; Suva ML; Bernstein BE; Alani R; Golub TR; Cole PA; Filbin MG; Shi Y
    Cancer Cell; 2019 Nov; 36(5):528-544.e10. PubMed ID: 31631026
    [TBL] [Abstract][Full Text] [Related]  

  • 59. H3K27me3 in Diffuse Midline Glioma and Epithelial Ovarian Cancer: Opposing Epigenetic Changes Leading to the Same Poor Outcomes.
    Day CA; Hinchcliffe EH; Robinson JP
    Cells; 2022 Oct; 11(21):. PubMed ID: 36359771
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Pre-Clinical Study of Panobinostat in Xenograft and Genetically Engineered Murine Diffuse Intrinsic Pontine Glioma Models.
    Hennika T; Hu G; Olaciregui NG; Barton KL; Ehteda A; Chitranjan A; Chang C; Gifford AJ; Tsoli M; Ziegler DS; Carcaboso AM; Becher OJ
    PLoS One; 2017; 12(1):e0169485. PubMed ID: 28052119
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.